Aardvark Therapeutics, Inc. Common Stock
NASDAQ: AARD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Tien-Li Lee
- Employees
- 22
- Headquarters
- San Diego, United States
- IPO year
- 2025
- Market cap
- $108.2M
- Website
- https://aardvarktherapeutics.com
Loading AARD…
Loading profile data…Frequently asked questions about AARD
What does Aardvark Therapeutics, Inc. Common Stock (AARD) do?
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an oral...
Where does AARD trade?
Aardvark Therapeutics, Inc. Common Stock (AARD) trades on the NASDAQ Global Select.
What sector is AARD in?
Aardvark Therapeutics, Inc. Common Stock (AARD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aardvark Therapeutics, Inc. Common Stock?
Tien-Li Lee is the chief executive officer of Aardvark Therapeutics, Inc. Common Stock (AARD).
Where is Aardvark Therapeutics, Inc. Common Stock headquartered?
Aardvark Therapeutics, Inc. Common Stock is headquartered in United States.
Does AARD pay a dividend?
Aardvark Therapeutics, Inc. Common Stock (AARD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AARD go public?
Aardvark Therapeutics, Inc. Common Stock (AARD) completed its initial public offering in 2025.